Results 91 to 100 of about 2,780 (190)
Novel PP2A biomarkers in cancer [PDF]
, 2021 Inhibition of tumor suppressor Protein Phosphatase 2A (PP2A) has been denoted as one of the minimal requirements for malignant transformation of a human cell.
Mäkelä, Eleonora
core
Global Challenges, Volume 9, Issue 1, January 2025.This review focuses on the challenges in the treatment of hepatocellular carcinoma (HCC) and how lipid nanoparticles (LNPs) have demonstrated considerable efficacy in the delivery of nucleic acid‐based therapeutics and have shown potential in chemotherapy, immunotherapy, and gene therapy.
Mingxuan Zhang +3 more
wiley +1 more source
Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer
Cancer Medicine, 2018 Preoperative (chemo)radiotherapy, (C)RT, is an essential part of the treatment of rectal cancer patients, but tumor response to this therapy among patients is variable. Thus far, there are no clinical biomarkers that could be used to predict response to (
Eva‐Maria Birkman +8 more
doaj +1 more source
Recent advances in noncoding RNA modifications of gastrointestinal cancer
Cancer Science, Volume 116, Issue 1, Page 8-20, January 2025.Functional overview of RNA modifications. Some modifications of microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) activate and others inactivate signals that promote cancer progression. Abstract Elucidating the mechanisms underlying cancer development and proliferation is important for the development of therapeutic ...
Tomoaki Hara +10 more
wiley +1 more source
Effect of Propolis on PPP2R1A and Apoptosis in Cancer Cells
Biochemistry Research International, Volume 2025, Issue 1, 2025.Recently, it has been shown that protein phosphatase 2A (PP2A) dysfunction was common in many cancer types and was mediated by various inactivation mechanisms. Although many research studies observed antitumor effect of propolis extracts in various types of cancer, the mechanism of effect are still obscure.
Burak Durmaz +8 more
wiley +1 more source
CIP2A is a critical DNA damage response protein that drives basal-like breast cancer [PDF]
, 2023 Basal-like breast cancer (BLBC) is an aggressive and therapeutically most challenging breast cancer subtype, due to a lack of druggable breast specific surface receptors (ER, PR, HER2) or driver mechanisms.
Nagelli, Srikar
core
Journal of Pharmacological Sciences, 2019 Acute myeloid leukemia (AML) is the most common subtype of hematological malignancy in humans, and its incidence increases with age. The treatment of AML still faces challenges.
Wenjing Ma +10 more
doaj +1 more source
FEBS Open Bio, 2020 Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers.
Eiji Nishio +8 more
doaj +1 more source
Advanced Science, Volume 11, Issue 36, September 25, 2024.The schematic illustrates how PP2Ac mediates autophagy during osteoclastogenesis in the subchondral bone in early osteoarthritis (OA). PP2Ac plays a significant role in regulating autophagy through its involvement in mTORC1 and the phosphorylation of ULK1.
Haifeng Zhang +13 more
wiley +1 more source
Serving up health: How phytochemicals transform food into medicine in the battle against cancer
Food Frontiers, Volume 5, Issue 5, Page 1866-1908, September 2024.Phytochemicals from fruits and vegetables exhibit anticancer activity through multiple mechanisms, with the Nrf2 pathway being one of the most important. Under oxidative stress, Nrf2 is released from Keap1, translocates to the nucleus, and activates antioxidant response elements (ARE), leading to increased antioxidant enzyme expression.
Eshita Sharma +10 more
wiley +1 more source